IL-4 and IL-13 inhibition in atopic dermatitis

Journal of Drugs in Dermatology

Volumn 15, Issue 8, 2016, Pages 925-929

  Matsunaga, Matthew C ^a   Yamauchi, Paul S ^b,c  

^a UNIVERSITY OF MINNESOTA MEDICAL SCHOOL   (United States)

^b Skin Care Center   (United States)

^c UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

INTERLEUKIN 13; INTERLEUKIN 4; BIOLOGICAL PRODUCT; DUPILUMAB; IL4 PROTEIN, HUMAN; INTERLEUKIN-13, HUMAN; MONOCLONAL ANTIBODY;

ARTICLE; ATOPIC DERMATITIS; B LYMPHOCYTE; BLOOD; EOSINOPHIL; HUMAN; MACROPHAGE; PATHOGENESIS; SKIN WATER LOSS; SYSTEMATIC REVIEW; T LYMPHOCYTE; TH2 CELL; ANIMAL; ANTAGONISTS AND INHIBITORS; DERMATITIS, ATOPIC; IMMUNOLOGY; METABOLISM; PROCEDURES; RANDOMIZED CONTROLLED TRIAL (TOPIC);

ANIMALS; ANTIBODIES, MONOCLONAL; BIOLOGICAL PRODUCTS; DERMATITIS, ATOPIC; HUMANS; INTERLEUKIN-13; INTERLEUKIN-4; RANDOMIZED CONTROLLED TRIALS AS TOPIC;

EID: 85021388980     PISSN: 15459616     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (62)

1. Shaw TE, Currie GP, Koudelka CW, et al. Eczema prevalence in the United States: data from the 2003 National Survey of Children's Health. J Invest Dermatol. 2011;131:67-73.
2. Beasley R. Worldwide variation in prevalence of symptoms of asthma, allergic rhinoconjunctivitis, and atopic eczema: ISAAC. Lancet. 1998;351:1225-32.
3. Kay J, Gawkrodger DJ, Mortimer MJ, et al. The prevalence of childhood atopic eczema in a general population. J Am Acad Dermatol. 1994;30:35-9.
4. Odhiambo JA, Williams HC, Clayton TO, et al. Global variations in prevalence of eczema symptoms in children from ISAAC Phase Three. J Allergy Clin Immunol. 2009;124:1251-8.
5. Ellis CN, Mancini AJ, Paller AS, et al. Understanding and managing atopic dermatitis in adult patients. Semin Cutan Med Surg. 2012;31(3 Suppl):S18-22.
6. Bieber T. Atopic dermatitis. Ann Dermatol. 2010;22:125-37.
7. van der Heijden FL, Wierenga EA, Bos JD, et al. High frequency of IL-4-producing CD4+allergenspecific T-lymphocytes in atopic dermatitis lesional skin. J Invest Dermatol. 1991;97:389-94.
8. Howard M, Paul WE. Interleukins for beta-lymphocytes. Lymphokine Res. 1982;1(1):1-4.
9. Minty A, Chalon P, Derocq JM, et al. Interleukin-13 is a new human lymphokine regulating inflammatory and immune responses. Nature. 1993;362:248-50.
10. McKenzie AN, Culpepper JA, de Waal Malefyt R, et al. Interleukin 13, a T-cellderived cytokine that regulates human monocyte and B-cell function. Proc Natl Acad Sci USA. 1993;90:3735-9.
11. van Leeuwen BH, Martinson ME, Webb GC, et al. Molecular organization of the cytokine gene cluster involving the human IL-3, IL-4, IL-5, and GM-CSF genes, on human chromosome 5. Blood. 1989;73:1142-8.
12. Dolganov G, Bort S, Lovett M, et al. Coexpression of the interleukin-13 and interleukin-4 genes correlates with their physical linkage in the cytokine gene cluster on human chromosome 5q23-31. Blood. 1996;87:3316-26.
13. Tandup S, Srivastava L, Harn DA Jr. Polarization of host immune responses by helminth-expressed glycans. Ann NY Acad Sci. 2012 Apr;1243:E1-E13.
14. PubMed Gene. IL4R interleukin 4 receptor [Homo sapiens (human)]. Available at http://www.ncbi.nlm.nih.gov/gene/3566. Accessed 4/10/2015.
15. Zurawski SM, Chomarat P, Djossou O, et al. The primary binding subunit of the human interleukin-4 receptor is also a component of the interleukin-13 receptor. J Biol Chem. 1995;270:13869-78.
16. Yang LP, Byun DG, Demeure CE, et al. Default development of cloned human naïve CD4 T cells into interleukin-4-and interleukin-5-producing effector cells. Eur J Immunol. 1995;25:3517-20.
17. Muller KM, Jaunin F, Masouye I, et al. Th2 cells mediate IL-4-dependent local tissue inflammation. J Immunol. 1993;150:5576-84.
18. Chan LS, Robinson N, Xu L. Expression of interleukin-4 in the epidermis of transgenic mice results in a pruritic inflammatory skin disease: an experimental animal model to study atopic dermatitis. J Invest Dermatol. 2001;117:977-83.
19. Lee GR, Flavell RA. Transgenic mice which overproduce Th2 cytokines develop spontaneous atopic dermatitis and asthma. Int Immunol. 2004;16:1155-60.
20. Brandt EB, Sivaprasad U. Th2 cytokines and atopic dermatitis. J Clin Cell Immunol. 2011;2:110-34.
21. Herrick CA, Xu L, McKenzie AN, et al. IL-13 is necessary, not simply sufficient, for epicutaneously induced Th2 responses to soluble protein antigen. J Immunol. 2003;170:2488-95.
22. Zheng R, Oh MH, Oh SY, et al. Transgenic expression of interleukin-13 in the skin induces a pruritic dermatitis and skin remodeling. J Invest Dermatol. 2009;129:742-51.
23. La Grutta S, Richiusa P, Pizzolanti G, et al. CD4(+)IL-13(+) cells in peripheral blood well correlates with the severity of atopic dermatitis in children. Allergy. 2005;60:391-5.
24. Sivaprasad U, Warrier MR, Gibson AM, et al. IL-13R? has a protective role in a mouse model of cutaneous inflammation. J Immunol. 2010;185:6802-8.
25. Metwally SS, Mosaad YM, Abdel-Samee ER, et al. IL-13 gene expression in patients with atopic dermatitis: relation to IgE level and to disease severity. Egypt J Immunol. 2004;11:171-7.
26. Borres MP, Bjorksten B. Peripheral blood eosinophils and IL-4 in infancy in relation to the appearance of allergic diseases during the first 6 years of life. Pediatr Allergy Immunol. 2004;15:216-20.
27. Lange J, Ngoumou G, Berkenheide S, et al. High interleukin-13 production by phytohaemagglutininand Der p 1-stimulated cord blood mononuclear cells is associated with the subsequent development of atopic dermatitis at the age of 3 years. Clin Exp Allergy. 2003;33:1537-43.
28. He JQ, Chan-Yeung M, Becker AB, et al. Genetic variants of the IL-13 and IL-4 genes and atopic diseases in at-risk children. Genes Immun. 2003 Jul;4(5):385-9.
29. Reich K, Westphal G, Konig IR, et al. Cytokine gene polymorphisms in atopic dermatitis. Br J Dermatol. 2003;148:1237-41.
30. Howell MD, Kim BE, Gao P, et al. Cytokine modulation of atopic dermatitis filaggrin skin expression. J Allergy Clin Immunol. 2007;120:150-5.
31. Pellerin L, Henry J, Hsu CY, et al. Defects of filaggrin-like proteins in both lesional and nonlesional atopic skin. J Allergy Clin Immunol. 2013;131:1094-102.
32. Tsuchisaka A, Furumura M, Hashimoto T. Cytokine regulation during epidermal differentiation and barrier formation. J Invest Dermatol. 2014;134:1194-6.
33. Omori-Miyake M, Yamashita M, Tsunemi Y, et al. In vitro assessment of IL-4 or IL-13-mediated changes in the structural components of keratinocytes in mice and humans. J Invest Dermatol. 2014;134:1342-50.
34. Hatano Y, Adachi Y, Elias PM, et al. The Th2 cytokine, interleukin-4, abrogates the cohesion of normal stratum corneum in mice: implications for pathogenesis of atopic dermatitis. Exp Dermatol. 2013;22:30-5.
35. PubMed Gene. KLK7 kallikrein-related peptidase 7 [Homo sapiens (human)]. Available at http://www.ncbi.nlm.nih.gov/gene/5650. Accessed 4/11/2015.
36. Morizane S, Yamasaki K, Kajita A, et al. Th2 cytokines increase kallikrein 7 expression and function in atopic dermatitis. J Allergy Clin Immunol. 2012;130:259-61.
37. Komatsu N, Saijoh K, Kuk C, et al. Human tissue kallikrein expression in the stratum corneum and serum of atopic dermatitis patients. Exp Dermatol. 2007;16:513-9.
38. Da Silva SC, Sahu RP, Konger RL, et al. Increased skin barrier disruption by sodium lauryl sulfate in mice expressing a constitutively active STAT6 in T cells. Arch Dermatol Res. 2012;304:65-71.
39. Nishi N, Yamamoto S, Ou W, et al. Enhanced CCL26 production by IL-4 through IFN-gamma-induced upregulation of type 1 IL-4 receptor in keratinocytes. Biochem Biophys Res Commun. 2008;376:234-40.
40. Gahr N, Folster-Holst R, Weichenthal M, et al. Dermal fibroblasts from acute inflamed atopic dermatitis lesions display increased eotaxin/CCL11 responsiveness to interleukin-4 stimulation. Br J Dermatol. 2011;164:586-92.
41. Bae SJ, Lee JB, Shimizu K, et al. Increase effect of transforming growth factor on eotaxin production by normal cultured dermal fibroblasts stimulated with interleukin-4: inhibitory effect of suplatast tosilate on eotaxin production. Immunol Invest. 2010;39:93-102.
42. Dubois GR, Bruijnzeel-Koomen CA, Bruijnzeel PL. IL-4 induces chemotaxis of blood eosinophils from atopic dermatitis patients, but not from normal individuals. J Invest Dermatol. 1994;102:843-6.
43. Elbe-Burger A, Egyed A, Olt S, et al. Overexpression of IL-4 alters the homeostasis in the skin. J Invest Dermatol. 2002;118:767-78.
44. Park SJ, Lee YH, Lee KH, et al. Effect of eriodictyol on the development of atopic dermatitis-like lesions in ICR mice. Biol Pharm Bull. 2013;36:1375-9.
45. Brauweiler AM, Goleva E, Leung DY. Th2 cytokines increase Staphylococcus aureus alpha toxininduced keratinocyte death through the signal transducer and activator of transcription 6 (STAT6). J Invest Dermatol. 2014;134:2114-21.
46. Bao L, Shi VY, Chan LS. IL-4 up-regulates epidermal chemotactic, angiogenic, and pro-inflammatory genes and down-regulates antimicrobial genes in vivo and in vitro: relevant in the pathogenesis of atopic dermatitis. Cytokine. 2013;61:419-25.
47. Perez-G M, Melo M, Keegan AD, et al. Aspirin and salicylates inhibit the IL-4-and IL-13-induced activation of STAT6. J Immunol. 2002;168:1428-34.
48. Wurster AL, Tanaka T, Grusby MJ. The biology of Stat4 and Stat6. Oncogene. 2000;19:2577-84.
49. Akimoto T, Numata F, Tamura M, et al. Abrogation of bronchial eosinophilic inflammation and airway hyperreactivity in signal transducers and activators of transcription (STAT)6-deficient mice. J Exp Med. 1998;187:1537-42.
50. Kuperman D, Schofield B, Wills-Karp M, et al. Signal transducer and activator of transcription factor 6 (stat6)-deficient mice are protected from antigen-induced airway hyperresponsiveness and mucus production. J Exp Med. 1998;187:939-48.
51. Kim MS, Kim JE, Yoon YS, et al. Improvement of atopic dermatitis-like skin lesions by IL-4 inhibition of P14 protein isolated from Lactobacillus casei in NC/Nga mice. Appl Microbiol Biotechnol. 2015 Feb 17[Epub ahead of print].
52. Yesilova Y, Calka O, Akdeniz N, et al. Effect of probiotics on the treatment of children with atopic dermatitis. Ann Dermatol. 2012;24:189-93.
53. da Costa Baptista IP, Accioly E, de Carvalho Padilha P. Effect of the use of probiotics in the treatment of children with atopic dermatitis; a literature review. Nutr Hosp. 2013;28:16-26.
54. Chan CC, Liou CJ, Xu PY, et al. Effect of dehydroepiandrosterone on atopic dermatitis-like skin lesions induced by 1-chloro-2,4-dinitrobenzene in mouse. J Dermatol Sci. 2013;72:149-57.
55. Kim ST, Lee KM, Park HJ, et al. Topical delivery of interleukin-13 antisense oligonucleotides with cationic elastic liposome for the treatment of atopic dermatitis. J Gene Med. 2009;11:26-37
56. Morioka T, Yamanake K, Mori H, et al. IL-4/IL-13 antagonist DNA vacciation successfully suppresses Th2 type chronic dermatitis. Br J Dermatol. 2009;160:1172-9.
57. Nakanishi T, Yamanaka K, Kakeda M, et al. Mutant interleukin-4/13 signaling blockade successfully suppresses acute phase inflammation. Arch Dermatol Res. 2013;305:241-7.
58. Eichenfield LF, Tom WL, Berger TG, et al. Guidelines of care for the management of atopic dermatitis. Section 2. Management and treatment of atopic dermatitis with topical therapies. J Am Acad Dermatol. 2014;71:116-32.
59. Sidbury R, Davis DM, Cohen DE, et al. Guidelines of care for the management of atopic dermatitis. Section 3. Management and treatment with phototherapy and systemic agents. J Am Acad Dermatol. 2014;71:327-49.
60. Beck LA, Thaci D, Hamilton JD, et al. Dupilumab treatment in adults with moderate-to-severe atopic dermatitis. N Engl J Med. 2014;371:130-9.
61. Hanania NA, Noonan M, Corren J, et al. Lebrikizumab in moderate-to-severe asthma: pooled data from two randomised placebo-controlled studies. Thorax. 2015 Aug;70(8):748-56.
62. Brightling CE, Chanez P, Leigh R, et al. Efficacy and safety of tralokinumab in patients with severe uncontrolled asthma: a randomised, double-blind, placebo-controlled, phase 2b trial. Lancet Respir Med. 2015 Jul 28. [Epub ahead of print]